Therapy Path Becomes Clear for Charcot-Marie-Tooth Disease

by Ramya Rachamanti on  November 8, 2019 at 5:22 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

Drug molecule embelin can prevent the inherited neurological disease named Charcot-Marie-Tooth (CMT). It can quell many key symptoms, including motor deficits, according to a study that appears in Nature Communications by Yang and her team.
Therapy Path Becomes Clear for Charcot-Marie-Tooth Disease
Therapy Path Becomes Clear for Charcot-Marie-Tooth Disease

CMT is a progressive disease that typically develops early in life, affecting roughly 1 in 2,500 people. Over time, the disease inflicts damage on patients' peripheral nervous system--which extends from the spinal cord into the hands and feet--often resulting in difficulties with balance, walking and fine motor skills such as writing or buttoning a shirt.

Show Full Article

The approach centers on enzymes known as aminoacyl-tRNA synthetases (aaRSs), which are pervasive throughout the body. They are the largest protein family linked to CMT disease, and also the long-running research specialty of Yang's lab.

These enzymes are essential to life because they kick off the first step of making new proteins, which are the building blocks of everything from blood and hormones to skin and bones. But in patients with CMT, some of the aaRS enzymes don't function as they should. As a result, peripheral neurons aren't made properly and become toxic to the peripheral nervous system.

In her search for a potential treatment approach, Yang wanted to find out why the mutated enzymes only seem to affect peripheral neurons. She discovered that while aaRS enzymes typically function in a part of the cell known as the cytoplasm, one mutated form of the enzyme known as TyrRS--which is known to be linked to the disease--exists inside a cell's nucleus.

"The nucleus is the site for gene expression or transcription to take place, which made this finding of special interest to us," Yang says. "Transcription regulates the identity of cells and cell-specific maintenance programs, and if something goes awry during this process, disease can result."

Fueled by the excitement of her nucleus discovery, Yang collaborated with Albena Jordanova, PhD, at the University of Antwerp. Jordanova is the scientist who first linked the mutant TyrRS enzyme to CMT disease and established a fruit fly model that exhibits CMT, enabling disease-focused research efforts.

Working together, the teams conducted experiments on fruit flies that showed "unequivocally" that the location of TyrRS in the nucleus was contributing to disease in a significant way. Then, by using a small-molecule drug called embelin to keep the enzyme from entering the nucleus, the team "achieved a complete rescue" of a fruit fly with CMT disease.

Yang noted that the discovery is most immediately relevant for patients who have a form of the disease known to be caused by mutant TyrRS. However, the findings may translate to subtypes caused by other mutant aaRS enzymes.

"This work paves the way for developing a viable therapy for CMT patients affected by TyrRS mutations," Yang says. "We're excited to advance this research by further validating the therapeutic approach and finding the best-possible pharmaceutical product to inhibit this enzyme from entering the nucleus. We also will investigate whether the nuclear relevance can be generalized to other CMT subtypes."

Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

News A - Z


News Search

Premium Membership Benefits

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive